m6A-centered Drug Response Information

General Information of the Drug (ID: M6ADRUG0108)
Name
STM2457
Synonyms
STM2457, STM-2457, CHEBI:172325, STM 2457, N-((6-(((cyclohexylmethyl)amino)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide, N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[6-[(cyclohexylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide, N-((6-(((cyclohexylmethyl)amino)methyl)imidazo(1,2-a)pyridin-2-yl)methyl)-4-oxo-4H-pyrido(1,2-a)pyrimidine-2-carboxamide, N-((6-((cyclohexylmethylamino)methyl)imidazo(1,2-a)pyridin-2-yl)methyl)-4-oxopyrido(1,2-a)pyrimidine-2-carboxamide, 2499663-01-1, CHEMBL5291234, SCHEMBL22499068, GTPL11529, EX-A5018, STM2457, BDBM50611061, s9870, AKOS040759643, AT32657, AC-36769, MS-28015, HY-134836, CS-0159584, N-((6-((Cyclohexylmethylamino)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide, N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide, STM2457, STM-2457, CHEBI:172325, STM 2457, N-((6-(((cyclohexylmethyl)amino)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide, N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[6-[(cyclohexylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide, N-((6-(((cyclohexylmethyl)amino)methyl)imidazo(1,2-a)pyridin-2-yl)methyl)-4-oxo-4H-pyrido(1,2-a)pyrimidine-2-carboxamide, N-((6-((cyclohexylmethylamino)methyl)imidazo(1,2-a)pyridin-2-yl)methyl)-4-oxopyrido(1,2-a)pyrimidine-2-carboxamide, 2499663-01-1, CHEMBL5291234, SCHEMBL22499068, GTPL11529, EX-A5018, STM2457, BDBM50611061, s9870, AKOS040759643, AT32657, AC-36769, MS-28015, HY-134836, CS-0159584, N-((6-((Cyclohexylmethylamino)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide, N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide
    Click to Show/Hide
Structure
3D MOL
2D MOL
Formula
C25H28N6O2
InChI
InChI=1S/C25H28N6O2/c32-24-12-21(29-23-8-4-5-11-31(23)24)25(33)27-15-20-17-30-16-19(9-10-22(30)28-20)14-26-13-18-6-2-1-3-7-18/h4-5,8-12,16-18,26H,1-3,6-7,13-15H2,(H,27,33)
InChIKey
OBERVORNENYOLE-UHFFFAOYSA-N
PubChem CID
155167581
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Drug
In total 6 item(s) under this drug
Crosstalk ID: M6ACROT05976
 Crosstalk Info 
m6A Regulator Methyltransferase-like 14 (METTL14)
 Regulator Info 
m6A Target Calcium-binding and coiled-coil domain-containing protein 1 (CALCOCO1)
 Target Gene 
Epigenetic Regulator DNA (cytosine-5)-methyltransferase 3B (DNMT3B)
Regulated Target Methyltransferase-like protein 14 (METTL14)
Crosstalk relationship DNA modification → m6A
Disease Breast cancer
 Disease Info 
Crosstalk ID: M6ACROT05977
 Crosstalk Info 
m6A Regulator Methyltransferase-like 14 (METTL14)
 Regulator Info 
m6A Target Sequestosome-1 (SQSTM1)
 Target Gene 
Epigenetic Regulator DNA (cytosine-5)-methyltransferase 3B (DNMT3B)
Regulated Target Methyltransferase-like protein 14 (METTL14)
Crosstalk relationship DNA modification → m6A
Disease Breast cancer
 Disease Info 
Crosstalk ID: M6ACROT05978
 Crosstalk Info 
m6A Regulator Methyltransferase-like 14 (METTL14)
 Regulator Info 
m6A Target Calcium-binding and coiled-coil domain-containing protein 1 (CALCOCO1)
 Target Gene 
Epigenetic Regulator Cysteine methyltransferase DNMT3A (DNMT3A)
Regulated Target Methyltransferase-like protein 14 (METTL14)
Crosstalk relationship DNA modification → m6A
Disease Breast cancer
 Disease Info 
Crosstalk ID: M6ACROT05979
 Crosstalk Info 
m6A Regulator Methyltransferase-like 14 (METTL14)
 Regulator Info 
m6A Target Sequestosome-1 (SQSTM1)
 Target Gene 
Epigenetic Regulator Cysteine methyltransferase DNMT3A (DNMT3A)
Regulated Target Methyltransferase-like protein 14 (METTL14)
Crosstalk relationship DNA modification → m6A
Disease Breast cancer
 Disease Info 
Crosstalk ID: M6ACROT05980
 Crosstalk Info 
m6A Regulator Methyltransferase-like 14 (METTL14)
 Regulator Info 
m6A Target Calcium-binding and coiled-coil domain-containing protein 1 (CALCOCO1)
 Target Gene 
Epigenetic Regulator DNA (cytosine-5)-methyltransferase 1 (DNMT1)
Regulated Target Methyltransferase-like protein 14 (METTL14)
Crosstalk relationship DNA modification → m6A
Disease Breast cancer
 Disease Info 
Crosstalk ID: M6ACROT05981
 Crosstalk Info 
m6A Regulator Methyltransferase-like 14 (METTL14)
 Regulator Info 
m6A Target Sequestosome-1 (SQSTM1)
 Target Gene 
Epigenetic Regulator DNA (cytosine-5)-methyltransferase 1 (DNMT1)
Regulated Target Methyltransferase-like protein 14 (METTL14)
Crosstalk relationship DNA modification → m6A
Disease Breast cancer
 Disease Info 
References
Ref 1 Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9. doi: 10.1056/NEJMoa1413654.
Ref 2 Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol. 2005 Aug;97(2):104-8. doi: 10.1111/j.1742-7843.2005.pto_134.x.
Ref 3 Interactions between riluzole and ABCG2/BCRP transporter. Neurosci Lett. 2009 Mar 6;452(1):12-6. doi: 10.1016/j.neulet.2008.12.061. Epub 2009 Jan 6.
Ref 4 GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015. doi: 10.21037/tlcr-20-608.
Ref 5 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2. doi: 10.1182/blood-2004-04-1398. Epub 2004 Jul 13.
Ref 6 Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96. doi: 10.1111/j.1365-2982.2008.01222.x. Epub 2008 Dec 5.
Ref 7 ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):231-43. doi: 10.1007/s00210-008-0279-6. Epub 2008 Apr 8.
Ref 8 Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs. 2007 Jun;8(6):493-8.
Ref 9 Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem. 2003 Nov 28;278(48):47408-15. doi: 10.1074/jbc.M307687200. Epub 2003 Sep 16.
Ref 10 Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
Ref 11 Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14. doi: 10.1177/0091270003255921.
Ref 12 National Cancer Institute Drug Dictionary (drug id 740856).